London, Feb 16, 2026, 09:18 GMT — Regular session
- Haleon slipped roughly 0.8% shortly after the open in London.
- Investors are looking for guidance when full-year 2025 results land on Feb. 25.
- The stock remains near its 12-month high.
Shares of Haleon PLC slipped 0.8% to 405.8 pence by 0918 GMT in London on Monday. The consumer health group tracked lower.
Sellers nudged Haleon lower ahead of full-year results slated for next week. Shares have been hovering close to 12-month highs, so expectations for something unexpected look slim.
After a lull in company headlines, investors are combing through whatever tweaks the outlook for growth, prices, or costs. Monday saw only a slight move, yet it shapes expectations as the UK gears up for a packed reporting week.
Shares kicked off at 405.5 pence, down from Friday’s 409.2 pence close. Trading volume has already topped 24 million shares, according to London Stock Exchange data.
Haleon’s ADR edged up to $11.20 in New York, a gain of roughly 0.3% from the prior close, market data showed.
According to Haleon’s investor calendar, the company will report its full-year 2025 results on Feb. 25, and deliver a first-quarter trading update April 29.
Leadership at Haleon has already signaled some restructuring on the way. Back in January, the company outlined plans to reshape its operating model, aiming to “drive growth” and streamline the business for greater agility. Expect specifics to land with the Feb. 25 results, according to Haleon’s prior update. Haleon Corporate
Traders face the usual questions—can volumes stay resilient as pricing softens, and what margins can the group defend while still backing brands like Sensodyne, Advil and Centrum?
Still, the update isn’t without risk. Softer guidance, delays on efficiency goals, or hints that customers are opting for cheaper options could all weigh on a stock that’s already seen a sharp run-up in the last year.
